inno.N

Company Overview

innovate New & Next,
inno.N is making the leap towards becoming the next global bio health care company.

About inno.N

inno.N brings us closer to the long-awaited dreams of a healthier and more beautiful daily life by living up to its social responsibilities and rising up to the challenge.

innovate New & Next
We help chart
the next century.

Since its establishment in 1984, inno.N has tapped into the belief that its business was also helping chart the nation’s future. This belief has served and continues to serve the company well, as it has grown into one of the leading pharmaceutical firms in the nation.
Since its establishment in 1984, inno.N has gained competitiveness in the businesses of prescription drugs, active pharmaceutical ingredients, health supplements and beauty products.
Drawing on the company’s experience and knowhow in developing novel drugs, inno.N succeeded in launching ‘K-CAB’, the 30th novel drug to be developed and registered in Korea, to great acclaim. Building on this success, inno.N remains committed to growing into a global bio health company built on outstanding products and technologies that bring us closer to a healthier future.
  1. Year of
    establishment

    History

    1984

  2. Address

    239, Osongsaengmyeong 2-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do

    Location
  3. Annual
    revenue for

    2023

    8,289
    billion won

  4. Operating
    profits for

    2023

    659
    billion won

  5. Number of
    employees as of

    2023

    A total of
    1,709

Corporate PR

View more

Business Overview

inno.N operates the prescription drugs, health, and beauty businesses and is making a leap into a global pharmaceutical company through active exports and partnerships.

Key businesses

inno.N is targeting the global pharmaceutical&bio market beyond Korea with its portfolio of various chronic disease drugs. We are developing and supplying excellent drugs that improve the quality of life based on the potential that has been grown through blockbusters by developing K-CAB, Korea's 30th new drug, for the treatment of gastroesophageal reflux disease.
In the area of Health & Beauty, inno.N continues to be active. Examples include 'CONDITION', which has been the undisputed No. 1 market share since pioneering the hangover cure market in 1992, 'HUTGAESOO', a steady seller in the healthy RTD market, 'TEALOG', a zero-calorie ice tea, and 'BEWANTS', a slow-aging skincare brand. inno.N is solidifying its position as a healthcare partner with the life cycle of its customers.
  • Prescription drugs

    inno.N aims to become a global leader in supplying prescription drugs by offering high value-added products such as the blockbuster K-CAB, the biopharmaceuticals Epokine and intravenous fluids.
    Take a look at the products
  • HEALTH & BEVERAGE

    With the hangover relief product ‘Condition’ and the health supplement beverage ‘Oriental Raisin Water (Hutgaesoo)’, inno.N helps create a more beautiful future.
    Take a look at the products
  • BEAUTY

    The slow aging cosmetics brand ‘bewants’ and the premium hair care brand ‘ScalpMed’ help create a more beautiful future.
    Take a look at the products

Global businesses

Drawing on its global sales network and marketing capabilities that it has built up over the years, inno.N has been offering its prescription drugs, active pharmaceutical ingredients, and health and beauty products to global markets. Products are now exported to Japan, Southeast Asia and Latin America. Furthermore, inno.N is targeting various countries such as Europe.

Strategic alliances

With its specialized sales and marketing capabilities as well as strong R&D in novel and biological drugs, inno.N has been able to forge a number of strategic alliances with global pharmaceutical firms, both large and small. The alliances with multinational pharmaceutical firms, including AstraZeneca, Takeda, Eisai, Daiichi Sankyo, have allowed inno.N to make innovative drugs more widely available to the Korean market, and to export worldwide the novel drugs and biological drugs developed by inno.N, making the competitiveness of one of Korea’s leading bio and healthcare company well known around the world.
Country Partner company Products
Middle East, North Africa Tabuk Pharmaceuticals K-CAB
Spain mAbxience Denosumab
UK AstraZeneca Vivacor
USA Braintree K-CAB
USA Currax Silenor
Singapore Celltrion AP Madipine, Basen
Japan Kureha Kremezin
Japan Nippon Chemiphar Soleton
Japan Sumitomo Dainippon Almarl
Japan Eisai Decaquinon
Japan Daiichi Sankyo Banan, Vitamedin, Mevalotin
Japan Mitsubishi Tanabe Herben, Arobest
Japan Takeda Ceradoran, Basen
Japan RaQualia K-CAB
Switzerland Helsinn Aloxi, Akynzeo
Germany Helm Procalin
Austria Ever Pemta
Netherlands Glycostem oNKord
China NCPC EPO
China Luoxin K-CAB
Mexico Carnot K-CAB
Indonesia Kalbe K-CAB
Vietnam Lynh Farma K-CAB
Philippines MPPI K-CAB
Thailand Pond's Chemical K-CAB
Singapore UITC K-CAB
Malaysia Pharmaniaga K-CAB
India Dr. Reddy's K-CAB
Russia Dr. Reddy's K-CAB
South Africa Dr. Reddy's K-CAB
Ukraine Dr. Reddy's K-CAB
Kazakhstan Dr. Reddy's K-CAB
Uzbekistan Dr. Reddy's K-CAB
Belarus Dr. Reddy's K-CAB
Brazil Eurofarma K-CAB
TOP